Direct-to-consumer (DTC) advertising of rofecoxib [Vioxx] and celecoxib [Celebrex] increased the number of patients with osteoarthritis (OA) seen by physicians each month

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.519, 2007-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Direct-to-consumer (DTC) advertising of rofecoxib [Vioxx] and celecoxib [Celebrex] increased the number of patients with osteoarthritis (OA) seen by physicians each month

By  

Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Almost all physicians in Finland are against complete direct-to-consumer (DTC) advertising of prescription drugs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 457, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Cost effectiveness of celecoxib, rofecoxib in OA and RA

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 352, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cost effectiveness of celecoxib, rofecoxib in OA and RA

By  

Inpharma, Vol. 1, Iss. 1327, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Celecoxib and rofecoxib equally effective in knee OA

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite